



SDI Review Form 1.6

Journal Name:	Journal of Cancer and Tumor International
Manuscript Number:	Ms_JCTI_35710
Title of the Manuscript:	Evaluation of Efficacy of Gefinitib in Comparison with Chemotherapy in Patients with Non-Small Cell Lung Carcinoma from India.
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Well written manuscript. I have some suggestions. 1- Why did you use Chi-square test? 2- "Activation of downstream pathways of EGFR may improve prognosis"(Breast J. 2017 Jun 7. doi: 10.1111/tbj.12838) and (Prague Med Rep. 2016;117(4):145-152. doi: 10.14712/23362936.2016.15. Review) I suggest both of these uptodate studies for the references.	We thank the reviewer. 1. Chi-square test was recommended by our statistician and it is widely used in such cancer studies. A few links to such studies are given below: http://www.sciencedirect.com/science/article/pii/S2405630817300022 https://www.ncbi.nlm.nih.gov/pubmed/23534708 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477286/ 2. The references suggested were not found to be suitable for our study.
Minor REVISION comments		
Optional/General comments		